Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 16/20 | 0.76 |
| ▸ | LCK | P06239 | 14/20 | 0.76 |
| ▸ | TEK | Q02763 | 13/20 | 0.76 |
| ▸ | KDR | P35968 | 4/20 | 0.76 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.76 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.76 |
| ▸ | ABL1 | P00519 | 6/20 | 0.71 |
| ▸ | FYN | P06241 | 3/20 | 0.71 |
| ▸ | PTK6 | Q13882 | 4/20 | 0.70 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.65 |
| ▸ | EGFR | P00533 | 1/20 | 0.65 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.65 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.65 |
| ▸ | BACE1 | P56817 | 1/20 | 0.65 |
| ▸ | PRKDC | P78527 | 1/20 | 0.65 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4854954 | 1.00 | SRC (0.76) | SRCLCKTEKKDRLIMK1 | |
| SCHEMBL6434974 | 1.00 | SRC (0.76) | SRCLCKTEKKDRLIMK1 | |
| SCHEMBL5804580 | 0.95 | ABL1 (0.72) | SRCLCKTEKKDRLIMK1 | |
| SCHEMBL4822893 | 0.94 | SRC (0.73) | SRCLCKTEKKDRLIMK1 | |
| SCHEMBL4819139 | 0.91 | SRC (0.64) | SRCLCKTEKKDRLIMK1 | |
| SCHEMBL23847494 | 0.90 | LCK (0.84) | SRCLCKTEKKDRLIMK1 | |
| SCHEMBL4847861 | 0.90 | LCK (0.84) | SRCLCKTEKKDRLIMK1 | |
| SCHEMBL7152942 | 0.89 | SRC (0.60) | SRCLCKTEKKDRLIMK1 | |
| SCHEMBL5812440 | 0.88 | LCK (0.80) | SRCLCKTEKKDRLIMK1 | |
| SCHEMBL5786214 | 0.88 | SRC (0.68) | SRCLCKTEKKDRLIMK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7400979-B2 | Kinase inhibitors; genetic engineering | ABBOTT LABORATORIES (US) | 2008-07-15 | — | — | US | disclosed |
| US-6921763-B2 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| US-6660744-B1 | Kinase inhibitors | ABBOTT GMBH & CO. KG (DE) | 2003-12-09 | — | — | US | disclosed |
| US-20030175935-A1 | Method of identifying inhibitors of Lck | ABBVIE INC. | 2003-09-18 | — | — | US | disclosed |
| EP-1212327-B1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AG (DE) | 2003-08-20 | — | — | EP | disclosed |
| WO-2003020880-A2 | METHOD OF IDENTIFYING INHIBITORS OF LCK | ABBOTT LABORATORIES (US) | 2003-03-13 | — | — | WO | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030175935-A1 | Method of identifying inhibitors of Lck | LCK, FYN, ZAP70 | SRC 13/4885LCK 1/4885TEK 1629/4885 |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | SRC 1834/4885LCK 1011/4885TEK 1657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.